# Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

> **NCT01225211** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 312 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Lumacaftor
- **DRUG:** Ivacaftor
- **DRUG:** Lumacaftor Placebo
- **DRUG:** Ivacaftor Placebo

## Key facts

- **NCT ID:** NCT01225211
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2015-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225211, "Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01225211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*